PainChek Limited
PCK.AX
Australian Securities Exchange0.10
AUD
- -
- -
PainChek Limited
PCK.AX
(Australian Securities Exchange)
Recent
price
0.10
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- PainChek Limited develops and commercializes AI-driven pain assessment software to support best-practice pain management across healthcare settings globally. Its core product, the PainChek® Universal Pain Management App, utilizes artificial intelligence and facial recognition technology to automate pain evaluation, particularly for individuals unable to self-report pain such as those living with dementia. The app combines real-time facial muscle movement analysis with traditional pain scales, enabling detailed and personalized pain profiles for clinical decision-making. PainChek also offers PainChek® Analytics, providing extensive data insights on pain assessment outcomes to healthcare providers and organizations. The company operates primarily in Australia, Europe, the UK, and is expanding in the United States, targeting aged care, home care, and hospital sectors. PainChek was founded in 2014 and is headquartered in Brisbane, Australia. Recent major developments include a strategic expansion into the US market with a pending FDA De Novo clearance submission for its Adult App, aiming to become the first FDA-cleared pain assessment tool for aged care residents in the US. In 2024, PainChek established a reseller partnership with UK digital care software provider Nourish Care, enhancing its market penetration in the UK. It also expanded its Australian market reach through a reseller agreement with BESTMED. The company completed a A$5.0 million capital raise in early 2024 to support growth initiatives. PainChek has reported rapid international growth with over 12 million assessments completed worldwide and aims to broaden its footprint in home care and hospital sectors in 2025. Additionally, PainChek received a European patent for its pain assessment technology in 2024, reinforcing its intellectual property position. The company retains regulatory clearance as a medical device in Australia and Europe and continues to invest in R&D to advance its AI pain assessment capabilities.